March 18, 2024 03:56 PM EDT

Study suggests controversial patent review pathway is effective for biologics

Nicole DeFeudis

Editor

A new study out of Harvard Medical School and West Virginia University suggests that fighting prescription drug patents through the US Patent and Trademark Office …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Study suggests controversial patent review pathway is effective for biologics

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA OKs the first-ever self-administered vaccine, for flu

The drug lobby's lawsuit against the IRA finds a sign of life after appeals court ruling

Biotech VC firm outlines plans for $100M fund

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

Study sug­gests con­tro­ver­sial patent re­view path­way is ef­fec­tive for bi­o­log­ics

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Study suggests controversial patent review pathway is effective for biologics